1
|
Encapsulation Strategies for Pancreatic Islet Transplantation without Immune Suppression. CURRENT STEM CELL REPORTS 2021. [DOI: 10.1007/s40778-021-00190-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Santos AP, Chevallier SS, de Haan B, de Vos P, Poncelet D. Impact of electrostatic potential on microcapsule-formation and physicochemical analysis of surface structure: Implications for therapeutic cell-microencapsulation. J Biomater Appl 2021; 36:638-647. [PMID: 33541171 DOI: 10.1177/0885328221988979] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Cell-encapsulation is used for preventing therapeutic cells from being rejected by the host. The technology to encapsulate cells in immunoprotective biomaterials, such as alginate, commonly involves application of an electrostatic droplet generator for reproducible manufacturing droplets of similar size and with similar surface properties. As many factors influencing droplet formation are still unknown, we investigated the impact of several parameters and fitted them to equations to make procedures more reproducible and allow optimal control of capsule size and properties. We demonstrate that droplet size is dependent on an interplay between the critical electric potential (Uc,), the needle size, and the distance between the needle and the gelation bath, and that it can be predicted with the equations proposed. The droplet formation was meticulously studied and followed by a high-speed camera. The X-ray photoelectron analysis demonstrated optimal gelation and substitution of sodium with calcium on alginate surfaces while the atomic force microscopy analysis demonstrated a low but considerable variation in surface roughness and low surface stiffness. Our study shows the importance of documenting critical parameters to guarantee reproducible manufacturing of beads with constant and adequate size and preventing batch-to-batch variations.
Collapse
Affiliation(s)
- Ana Paula Santos
- Planta Piloto de Procesos Industriales Microbiologicos, Avenida Belgrano y pasaje Caseros, Tucumán, Argentina
| | | | - Bart de Haan
- University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Paul de Vos
- Immunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Denis Poncelet
- Oniris Nantes - Site de la Géraudière, Nantes, Pays de la Loire France.,EncapProcess, Suce sur Erdre, Pays de la Loire, France
| |
Collapse
|
3
|
Kupikowska-Stobba B, Lewińska D. Polymer microcapsules and microbeads as cell carriers for in vivo biomedical applications. Biomater Sci 2020; 8:1536-1574. [PMID: 32110789 DOI: 10.1039/c9bm01337g] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Polymer microcarriers are being extensively explored as cell delivery vehicles in cell-based therapies and hybrid tissue and organ engineering. Spherical microcarriers are of particular interest due to easy fabrication and injectability. They include microbeads, composed of a porous matrix, and microcapsules, where matrix core is additionally covered with a semipermeable membrane. Microcarriers provide cell containment at implantation site and protect the cells from host immunoresponse, degradation and shear stress. Immobilized cells may be genetically altered to release a specific therapeutic product directly at the target site, eliminating side effects of systemic therapies. Cell microcarriers need to fulfil a number of extremely high standards regarding their biocompatibility, cytocompatibility, immunoisolating capacity, transport, mechanical and chemical properties. To obtain cell microcarriers of specified parameters, a wide variety of polymers, both natural and synthetic, and immobilization methods can be applied. Yet so far, only a few approaches based on cell-laden microcarriers have reached clinical trials. The main issue that still impedes progress of these systems towards clinical application is limited cell survival in vivo. Herein, we review polymer biomaterials and methods used for fabrication of cell microcarriers for in vivo biomedical applications. We describe their key limitations and modifications aiming at improvement of microcarrier in vivo performance. We also present the main applications of polymer cell microcarriers in regenerative medicine, pancreatic islet and hepatocyte transplantation and in the treatment of cancer. Lastly, we outline the main challenges in cell microimmobilization for biomedical purposes, the strategies to overcome these issues and potential future improvements in this area.
Collapse
Affiliation(s)
- Barbara Kupikowska-Stobba
- Laboratory of Electrostatic Methods of Bioencapsulation, Department of Biomaterials and Biotechnological Systems, Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Trojdena 4, 02-109 Warsaw, Poland.
| | - Dorota Lewińska
- Laboratory of Electrostatic Methods of Bioencapsulation, Department of Biomaterials and Biotechnological Systems, Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Trojdena 4, 02-109 Warsaw, Poland.
| |
Collapse
|
4
|
Tzamaloukas AH. Effect of Edema on Urea Kinetic Studies in Peritoneal Dialysis Patients. Perit Dial Int 2020. [DOI: 10.1177/089686089401400416] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- Antonios H. Tzamaloukas
- Renal Section Veterans Affairs Medical Center University of New Mexico School of Medicine Albuquerque, New Mexico, U.S.A
| |
Collapse
|
5
|
Correia CR, Reis RL, Mano JF. Design Principles and Multifunctionality in Cell Encapsulation Systems for Tissue Regeneration. Adv Healthc Mater 2018; 7:e1701444. [PMID: 30102458 DOI: 10.1002/adhm.201701444] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 07/16/2018] [Indexed: 12/12/2022]
Abstract
Cell encapsulation systems are being increasingly applied as multifunctional strategies to regenerate tissues. Lessons afforded with encapsulation systems aiming to treat endocrine diseases seem to be highly valuable for the tissue engineering and regenerative medicine (TERM) systems of today, in which tissue regeneration and biomaterial integration are key components. Innumerous multifunctional systems for cell compartmentalization are being proposed to meet the specific needs required in the TERM field. Herein is reviewed the variable geometries proposed to produce cell encapsulation strategies toward tissue regeneration, including spherical and fiber-shaped systems, and other complex shapes and arrangements that better mimic the highly hierarchical organization of native tissues. The application of such principles in the TERM field brings new possibilities for the development of highly complex systems, which holds tremendous promise for tissue regeneration. The complex systems aim to recreate adequate environmental signals found in native tissue (in particular during the regenerative process) to control the cellular outcome, and conferring multifunctional properties, namely the incorporation of bioactive molecules and the ability to create smart and adaptative systems in response to different stimuli. The new multifunctional properties of such systems that are being employed to fulfill the requirements of the TERM field are also discussed.
Collapse
Affiliation(s)
- Clara R. Correia
- 3B's Research Group – Biomaterials, Biodegradables, and BiomimeticsUniversity of MinhoHeadquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine AvePark 4805‐017 Barco Guimarães Portugal
- ICVS/3B's – PT Government Associate Laboratory Braga/Guimarães Portugal
| | - Rui L. Reis
- 3B's Research Group – Biomaterials, Biodegradables, and BiomimeticsUniversity of MinhoHeadquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine AvePark 4805‐017 Barco Guimarães Portugal
- ICVS/3B's – PT Government Associate Laboratory Braga/Guimarães Portugal
| | - João F. Mano
- 3B's Research Group – Biomaterials, Biodegradables, and BiomimeticsUniversity of MinhoHeadquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine AvePark 4805‐017 Barco Guimarães Portugal
- ICVS/3B's – PT Government Associate Laboratory Braga/Guimarães Portugal
| |
Collapse
|
6
|
Abstract
The principle of immunoisolation of cells is based on encapsulation of cells in immunoprotective but semipermeable membranes that protect cells from hazardous effects of the host immune system but allows ingress of nutrients and outgress of therapeutic molecules. The technology was introduced in 1933 but has only received its deserved attention for its therapeutic application for three decades now.In the past decade important advances have been made in creating capsules that provoke minimal or no inflammatory responses. There are however new emerging challenges. These challenges relate to optimal nutrition and oxygen supply as well as standardization and documentation of capsule properties.It is concluded that the proof of principle of applicability of encapsulated grafts for treatment of human disease has been demonstrated and merits optimism about its clinical potential. Further innovation requires a much more systematic approach in identifying crucial properties of capsules and cellular grafts to allow sound interpretations of the results.
Collapse
Affiliation(s)
- Paul de Vos
- Division of Immuno-Endocrinology, Departments of Pathology and Laboratory Medicine, University of Groningen, Groningen, Groningen, The Netherlands.
| |
Collapse
|
7
|
Abstract
Biohybrid artificial organs encompass all devices which substitute for an organ or tissue function and incorporate both synthetic materials and living cells. This review concerns implantable immunoisolation devices in which the tissue is protected from immune rejection by enclosure within a semipermeable membrane. Two critical areas are discussed in detail: (i) Device design and performance as it relates to maintenance of cell viability and function. Attention is focussed on oxygen supply limitation and how it is affected by tissue density and the development of materials that induce neovascularization at the host tissue-membrane interface; and (ii) Protection from immune rejection. Our current knowledge of the mechanisms that may be operative in immune rejection in the presence of a semipermeable membrane barrier is limited. Nonetheless, recent studies shed light on the role played by membrane properties in preventing immune rejection, and many studies demonstrate substantial progress towards clinically useful implantable immunoisolation devices.
Collapse
Affiliation(s)
- C K Colton
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge 02139-4307, USA
| |
Collapse
|
8
|
Sayyar B, Dodd M, Marquez-Curtis L, Janowska-Wieczorek A, Hortelano G. Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2016; 43:318-27. [PMID: 24564349 DOI: 10.3109/21691401.2014.885446] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Continuous delivery of proteins by engineered cells encapsu-lated in biocompatible polymeric microcapsules is of considerable therapeutic potential. However, this technology has not lived up to expectations due to inadequate cell--matrix interactions and subsequent cell death. In this study we hypoth-esize that the presence of fibronectin in an alginate matrix may enhance the viability and functionality of encapsulated human cord blood-derived mesenchymal stromal cells (MSCs) expressing the human Factor IX (FIX) gene. MSCs were encapsulated in alginate-PLL microcapsules containing 10, 100, or 500 μg/ml fibronectin to ameliorate cell survival. MSCs in microcapsules with 100 and 500 μg/ml fibronectin demonstrated improved cell viability and proliferation and higher FIX secretion compared to MSCs in non-supplemented microcapsules. In contrast, 10 μg/ml fibronectin did not significantly affect the viability and protein secretion from the encapsulated cells. Differentiation studies demonstrated osteogenic (but not chondrogenic or adipogenic) differentiation capability and efficient FIX secretion of the enclosed MSCs in the fibronectin-alginate suspension culture. Thus, the use of recombinant MSCs encapsulated in fibronectin-alginate microcapsules in basal or osteogenic cultures may be of practical use in the treatment of hemophilia B.
Collapse
|
9
|
Llacua A, de Haan BJ, Smink SA, de Vos P. Extracellular matrix components supporting human islet function in alginate-based immunoprotective microcapsules for treatment of diabetes. J Biomed Mater Res A 2016; 104:1788-96. [PMID: 26990360 DOI: 10.1002/jbm.a.35706] [Citation(s) in RCA: 83] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 02/16/2016] [Accepted: 03/02/2016] [Indexed: 02/06/2023]
Abstract
In the pancreas, extracellular matrix (ECM) components play an import role in providing mechanical and physiological support, and also contribute to the function of islets. These ECM-connections are damaged during islet-isolation from the pancreas and are not fully recovered after encapsulation and transplantation. To promote the functional survival of human pancreatic islets, we tested different ECMs molecules in alginate-encapsulated human islets. These were laminin derived recognition sequences, IKVAV, RGD, LRE, PDSGR, collagen I sequence DGEA (0.01 - 1.0 mM), and collagen IV (50 - 200 µg/mL). Interaction with RGD and PDSGR promoted islet viability and glucose induced insulin secretion (GIIS) when it was applied at concentrations ranging from 0.01 - 1.0 mM (p < 0.05). Also the laminin sequence LRE contributed to enhanced GIIS but only at higher concentrations of 1 mM (p < 0.05). Collagen IV also had beneficial effects but only at 50 µg/ml and no further improvement was observed at higher concentrations. IKVAV and DGEA had no effects on human islets. Synergistic effects were observed by adding Collagen(IV)-RGD, Collagen(IV)-LRE, and Collagen(IV)-PDSGR to encapsulated human islets. Our results demonstrate the potential of specific ECM components in support of functional survival of human encapsulated and free islet grafts. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1788-1796, 2016.
Collapse
Affiliation(s)
- Alberto Llacua
- Department of Pathology and Medical Biology, Immunoendocrinology, University of Groningen, Hanzeplein 1, Groningen, RB, 9700, The Netherlands
| | - Bart J de Haan
- Department of Pathology and Medical Biology, Immunoendocrinology, University of Groningen, Hanzeplein 1, Groningen, RB, 9700, The Netherlands
| | - Sandra A Smink
- Department of Pathology and Medical Biology, Immunoendocrinology, University of Groningen, Hanzeplein 1, Groningen, RB, 9700, The Netherlands
| | - Paul de Vos
- Department of Pathology and Medical Biology, Immunoendocrinology, University of Groningen, Hanzeplein 1, Groningen, RB, 9700, The Netherlands
| |
Collapse
|
10
|
Spasojevic M, Paredes-Juarez GA, Vorenkamp J, de Haan BJ, Schouten AJ, de Vos P. Reduction of the inflammatory responses against alginate-poly-L-lysine microcapsules by anti-biofouling surfaces of PEG-b-PLL diblock copolymers. PLoS One 2014; 9:e109837. [PMID: 25347191 PMCID: PMC4209974 DOI: 10.1371/journal.pone.0109837] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2014] [Accepted: 09/03/2014] [Indexed: 01/12/2023] Open
Abstract
Large-scale application of alginate-poly-L-lysine (alginate-PLL) capsules used for microencapsulation of living cells is hampered by varying degrees of success, caused by tissue responses against the capsules in the host. A major cause is proinflammatory PLL which is applied at the surface to provide semipermeable properties and immunoprotection. In this study, we investigated whether application of poly(ethylene glycol)-block-poly(L-lysine hydrochloride) diblock copolymers (PEG-b-PLL) can reduce the responses against PLL on alginate-matrices. The application of PEG-b-PLL was studied in two manners: (i) as a substitute for PLL or (ii) as an anti-biofouling layer on top of a proinflammatory, but immunoprotective, semipermeable alginate-PLL100 membrane. Transmission FTIR was applied to monitor the binding of PEG-b-PLL. When applied as a substitute for PLL, strong host responses in mice were observed. These responses were caused by insufficient binding of the PLL block of the diblock copolymers confirmed by FTIR. When PEG-b-PLL was applied as an anti-biofouling layer on top of PLL100 the responses in mice were severely reduced. Building an effective anti-biofouling layer required 50 hours as confirmed by FTIR, immunocytochemistry and XPS. Our study provides new insight in the binding requirements of polyamino acids necessary to provide an immunoprotective membrane. Furthermore, we present a relatively simple method to mask proinflammatory components on the surface of microcapsules to reduce host responses. Finally, but most importantly, our study illustrates the importance of combining physicochemical and biological methods to understand the complex interactions at the capsules' surface that determine the success or failure of microcapsules applicable for cell-encapsulation.
Collapse
Affiliation(s)
- Milica Spasojevic
- Department of Polymer Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Groningen, The Netherlands
- Departments of Pathology and Laboratory Medicine, section of Medical Biology, division of immunoendocrinology, University of Groningen, Groningen, The Netherlands
| | - Genaro A. Paredes-Juarez
- Departments of Pathology and Laboratory Medicine, section of Medical Biology, division of immunoendocrinology, University of Groningen, Groningen, The Netherlands
| | - Joop Vorenkamp
- Department of Polymer Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Groningen, The Netherlands
| | - Bart J. de Haan
- Departments of Pathology and Laboratory Medicine, section of Medical Biology, division of immunoendocrinology, University of Groningen, Groningen, The Netherlands
| | - Arend Jan Schouten
- Department of Polymer Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Groningen, The Netherlands
| | - Paul de Vos
- Departments of Pathology and Laboratory Medicine, section of Medical Biology, division of immunoendocrinology, University of Groningen, Groningen, The Netherlands
| |
Collapse
|
11
|
de Vos P, Lazarjani HA, Poncelet D, Faas MM. Polymers in cell encapsulation from an enveloped cell perspective. Adv Drug Deliv Rev 2014; 67-68:15-34. [PMID: 24270009 DOI: 10.1016/j.addr.2013.11.005] [Citation(s) in RCA: 186] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Revised: 08/26/2013] [Accepted: 11/13/2013] [Indexed: 02/07/2023]
Abstract
In the past two decades, many polymers have been proposed for producing immunoprotective capsules. Examples include the natural polymers alginate, agarose, chitosan, cellulose, collagen, and xanthan and synthetic polymers poly(ethylene glycol), polyvinyl alcohol, polyurethane, poly(ether-sulfone), polypropylene, sodium polystyrene sulfate, and polyacrylate poly(acrylonitrile-sodium methallylsulfonate). The biocompatibility of these polymers is discussed in terms of tissue responses in both the host and matrix to accommodate the functional survival of the cells. Cells should grow and function in the polymer network as adequately as in their natural environment. This is critical when therapeutic cells from scarce cadaveric donors are considered, such as pancreatic islets. Additionally, the cell mass in capsules is discussed from the perspective of emerging new insights into the release of so-called danger-associated molecular pattern molecules by clumps of necrotic therapeutic cells. We conclude that despite two decades of intensive research, drawing conclusions about which polymer is most adequate for clinical application is still difficult. This is because of the lack of documentation on critical information, such as the composition of the polymer, the presence or absence of confounding factors that induce immune responses, toxicity to enveloped cells, and the permeability of the polymer network. Only alginate has been studied extensively and currently qualifies for application. This review also discusses critical issues that are not directly related to polymers and are not discussed in the other reviews in this issue, such as the functional performance of encapsulated cells in vivo. Physiological endocrine responses may indeed not be expected because of the many barriers that the metabolites encounter when traveling from the blood stream to the enveloped cells and back to circulation. However, despite these diffusion barriers, many studies have shown optimal regulation, allowing us to conclude that encapsulated grafts do not always follow nature's course but are still a possible solution for many endocrine disorders for which the minute-to-minute regulation of metabolites is mandatory.
Collapse
|
12
|
Transplantation of Encapsulated Pancreatic Islets as a Treatment for Patients with Type 1 Diabetes Mellitus. Adv Med 2014; 2014:429710. [PMID: 26556410 PMCID: PMC4590955 DOI: 10.1155/2014/429710] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Accepted: 11/30/2013] [Indexed: 12/19/2022] Open
Abstract
Encapsulation of pancreatic islets has been proposed and investigated for over three decades to improve islet transplantation outcomes and to eliminate the side effects of immunosuppressive medications. Of the numerous encapsulation systems developed in the past, microencapsulation have been studied most extensively so far. A wide variety of materials has been tested for microencapsulation in various animal models (including nonhuman primates or NHPs) and some materials were shown to induce immunoprotection to islet grafts without the need for chronic immunosuppression. Despite the initial success of microcapsules in NHP models, the combined use of islet transplantation (allograft) and microencapsulation has not yet been successful in clinical trials. This review consists of three sections: introduction to islet transplantation, transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus (T1DM), and present challenges and future perspectives.
Collapse
|
13
|
Mazzitelli S, Capretto L, Quinci F, Piva R, Nastruzzi C. Preparation of cell-encapsulation devices in confined microenvironment. Adv Drug Deliv Rev 2013; 65:1533-55. [PMID: 23933618 DOI: 10.1016/j.addr.2013.07.021] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2013] [Revised: 07/18/2013] [Accepted: 07/31/2013] [Indexed: 02/07/2023]
Abstract
The entrapment of cells into hydrogel microdevice in form of microparticles or microfibers is one of the most appealing and useful tools for cell-based therapy and tissue engineering. Cell encapsulation procedures allow the immunoisolation of cells from the surrounding environment, after their transplantation and the maintenance of the normal cellular physiology. Factors affecting the efficacy of microdevices, which include size, size distribution, morphology, and porosity are all highly dependent on the method of preparation. In this respect, microfluidic based methods offer a promising strategy to fabricate highly uniform and morphologically controlled microdevices with tunable chemical and mechanical properties. In the current review, various cell microencapsulation procedures, based on a microfluidics, are critically analyzed with a special focus on the effect of the procedure on the morphology, viability and functions of the embedded cells. Moreover, a brief introduction about the optimal characteristics of microdevice intended for cell encapsulation, together with the currently used materials for the production is reported. A further challenging application of microfluidics for the development of "living microchip" is also presented. Finally, the limitations, challenging and future work on the microfluidic approach are also discussed.
Collapse
Affiliation(s)
- Stefania Mazzitelli
- Department of Life Sciences and Biotechnology, University of Ferrara, Via F. Mortara 17/19, Ferrara 44121, Italy.
| | | | | | | | | |
Collapse
|
14
|
Spasojevic M, Bhujbal S, Paredes G, de Haan BJ, Schouten AJ, de Vos P. Considerations in binding diblock copolymers on hydrophilic alginate beads for providing an immunoprotective membrane. J Biomed Mater Res A 2013; 102:1887-96. [PMID: 23853069 PMCID: PMC4232034 DOI: 10.1002/jbm.a.34863] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 06/13/2013] [Accepted: 06/28/2013] [Indexed: 01/14/2023]
Abstract
Alginate-based microcapsules are being proposed for treatment of many types of diseases. A major obstacle however in the successes is that these capsules are having large lab-to-lab variations. To make the process more reproducible, we propose to cover the surface of alginate capsules with diblock polymers that can form polymer brushes. In the present study, we describe the stepwise considerations for successful application of diblock copolymer of polyethylene glycol (PEG) and poly-l-lysine (PLL) on the surface of alginate beads. Special procedures had to be designed as alginate beads are hydrophilic and most protocols are designed for hydrophobic biomaterials. The successful attachment of diblock copolymer and the presence of PEG blocks on the surface of the capsules were studied by fluorescence microscopy. Longer time periods, that is, 30–60 min, are required to achieve saturation of the surface. The block lengths influenced the strength of the capsules. Shorter PLL blocks resulted in less stable capsules. Adequate permeability of the capsules was achieved with poly(ethylene glycol)-block-poly(l-lysine hydrochloride) (PEG454-b-PLL100) diblock copolymers. The capsules were a barrier for immunoglobulin G. The PEG454-b-PLL100 capsules have similar mechanical properties as PLL capsules. Minor immune activation of nuclear factor κB in THP-1 monocytes was observed with both PLL and PEG454-b-PLL100 capsules prepared from purified alginate. Our results show that we can successfully apply block copolymers on the surface of hydrophilic alginate beads without interfering with the physicochemical properties.
Collapse
Affiliation(s)
- Milica Spasojevic
- Department of Polymer Chemistry, Zernike Institute for Advanced Materials, University of Groningen, 9747, AG Groningen, the Netherlands; Departments of Pathology and Laboratory Medicine, Section of Medical Biology, Division of Immunoendocrinology, University of Groningen, Hanzeplein 1, 9700, RB Groningen, The Netherlands
| | | | | | | | | | | |
Collapse
|
15
|
Sayyar B, Dodd M, Marquez-Curtis L, Janowska-Wieczorek A, Hortelano G. Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2013; 42:102-9. [DOI: 10.3109/21691401.2013.794354] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
16
|
Wieland M, Fussenegger M. Reprogrammed cell delivery for personalized medicine. Adv Drug Deliv Rev 2012; 64:1477-87. [PMID: 22721864 DOI: 10.1016/j.addr.2012.06.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Revised: 06/01/2012] [Accepted: 06/13/2012] [Indexed: 11/29/2022]
Abstract
In most approaches, personalized medicine requires time- and cost-intensive characterization of an individual's genetic background in order to achieve the best-adapted therapy. For this purpose, cell-based drug delivery offers a promising alternative. In particular, synthetic biology has introduced the vision of cells being programmable therapeutic production facilities that can be introduced into patients. This review highlights the progress made in synthetic biology-based cell engineering toward advanced drug delivery entities. Starting from basic one-input responsive transcriptional or post-transcriptional gene control systems, the field has reached a level on which cells can be engineered to detect cancer cells, to obtain control over T-cell proliferation, and to restore blood glucose homeostasis upon blue light illumination. Furthermore, a cellular implant was developed that detects blood urate level disorders and acts accordingly to restore homeostasis while another cellular implant was engineered as an artificial insemination device that releases bull sperm into bovine ovarian only during ovulation time by recording endogenous luteinizing hormone levels. Soon, the field will reach a stage at which cells can be reprogrammed to detect multiple metabolic parameters and self-sufficiently treat any disorder connected to them.
Collapse
Affiliation(s)
- Markus Wieland
- ETH Zurich, Department of Biosystems Science and Bioengineering (D-BSSE), Mattenstrasse 26, CH-4058 Basel, Switzerland
| | | |
Collapse
|
17
|
Bugaj LJ, Schaffer DV. Bringing next-generation therapeutics to the clinic through synthetic biology. Curr Opin Chem Biol 2012; 16:355-61. [DOI: 10.1016/j.cbpa.2012.04.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2012] [Accepted: 04/15/2012] [Indexed: 01/21/2023]
|
18
|
Ausländer S, Wieland M, Fussenegger M. Smart medication through combination of synthetic biology and cell microencapsulation. Metab Eng 2012; 14:252-60. [DOI: 10.1016/j.ymben.2011.06.003] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2011] [Revised: 05/11/2011] [Accepted: 06/09/2011] [Indexed: 01/05/2023]
|
19
|
de Haan BJ, Rossi A, Faas MM, Smelt MJ, Sonvico F, Colombo P, de Vos P. Structural surface changes and inflammatory responses against alginate-based microcapsules after exposure to human peritoneal fluid. J Biomed Mater Res A 2011; 98:394-403. [DOI: 10.1002/jbm.a.33123] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2010] [Revised: 02/09/2011] [Accepted: 03/25/2011] [Indexed: 11/06/2022]
|
20
|
de Vos P, Spasojevic M, Faas MM. Treatment of diabetes with encapsulated islets. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2010; 670:38-53. [PMID: 20384217 DOI: 10.1007/978-1-4419-5786-3_5] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
Cell encapsulation has been proposed for the treatment of a wide variety of diseases since it allows for transplantation of cells in the absence of undesired immunosuppression. The technology has been proposed to be a solution for the treatment of diabetes since it potentially allows a mandatory minute-to-minute regulation of glucose levels without side-effects. Encapsulation is based on the principle that transplanted tissue is protected for the host immune system by a semipermeable capsule. Many different concepts of capsules have been tested. During the past two decades three major approaches of encapsulation have been studied. These include (i) intravascular macrocapsules, which are anastomosed to the vascular system as AV shunt, (ii) extravascular macrocapsules, which are mostly diffusion chambers transplanted at different sites and (iii) extravascular microcapsules transplanted in the peritoneal cavity. The advantages and pitfalls of the three approaches are discussed and compared in view of applicability in clinical islet transplantation.
Collapse
Affiliation(s)
- Paul de Vos
- Department of Pathology and Laboratory Medicine, Section of Immunoendocrinology, University of Groningen. Hanzeplein 1, 9700 RB Groningen, The Netherlands.
| | | | | |
Collapse
|
21
|
Highlights and trends in cell encapsulation. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2010; 670:1-4. [PMID: 20384213 DOI: 10.1007/978-1-4419-5786-3_1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The exciting developments in the field of drug delivery have already had an enormous impact on medical technology, facilitating the administration of many drugs and improving the pharmacokinetics of many others. The past few years have also seen several firsts, including the design of novel tissue engineered approaches, intriguing advances in the fields of biomaterials and cell therapy and the improvements in the fabrication of more refined and tailored micro and nanocarriers for protein and drug delivery. The sinergy of some of these promising fields have fuelled the progress of cell encapsulation technology, a relatively old concept pioneered 60 years ago. The ability to combine cells and polymer scaffolds to create "living cell medicines" that provide long-term drug delivery has opened new doors in the use of allografts. In fact, transplanted cells may be isolated from the host's immune system by embedding them in a permeable device that controls the outward and inward diffusion of molecules and cells. As a result of this, the requirement for immunosuppresant drugs can be eliminated or at least reduced. At present, the burgeoning number of cutting edge discoveries is leading to the design ofbiomimetic and biodegradable microcarriers that can easily combined with stem cells. The latter will improve the protection and transport of the cells to the target injured tissue and then promote cell integration and consequently tissue repair or regeneration. In the present reviews, we discussed the state of the art in the field of cell encapsulation technology. This book describes the most relevant aspects of the design and development of cell-loaded microcapsules. Some of the most interesting therapeutic applications of this technology are presented as are some of the limitations, future challenges and directions in the field.
Collapse
|
22
|
Artificial cell microencapsulated stem cells in regenerative medicine, tissue engineering and cell therapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2010; 670:68-79. [PMID: 20384219 DOI: 10.1007/978-1-4419-5786-3_7] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Adult stem cells, especially isolated from bone marrow, have been extensively investigated in recent years. Studies focus on their multiple plasticity oftransdifferentiating into various cell lineages and on their potential in cellular therapy in regenerative medicine. In many cases, there is the need for tissue engineering manipulation. Among the different approaches of stem cells tissue engineering, microencapsulation can immobilize stem cells to provide a favorable microenvironment for stem cells survival and functioning. Furthermore, microencapsulated stem cells are immunoisolated after transplantation. We show that one intraperitoneal injection of microencapsulated bone marrow stem cells can prolong the survival of liver failure rat models with 90% of the liver removed surgically. In addition to transdifferentiation, bone marrow stem cells can act as feeder cells. For example, when coencapsulated with hepatocytes, stem cells can increase the viability and function of the hepatocytes in vitro and in vivo.
Collapse
|
23
|
Lim GJ, Zare S, Van Dyke M, Atala A. Cell microencapsulation. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2010; 670:126-36. [PMID: 20384223 DOI: 10.1007/978-1-4419-5786-3_11] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In the past several decades, many attempts have been made to prevent the rejection of transplanted cells by the immune system. Cell encapsulation is primary machinery for cell transplantation and new materials and approaches were developed to encapsulate various types of cells to treat a wide range of diseases. This technology involves placing the transplanted cells within a biocompatible membrane in attempt to isolate the cells from the host immune attack and enhance or prolong their function in vivo. In this chapter, we will review the situation of cell microencapsulation field and discuss its potentials and challenges for cell therapy and regeneration of tissue function.
Collapse
Affiliation(s)
- Grace J Lim
- Department of Urology, Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC 27157, USA
| | | | | | | |
Collapse
|
24
|
Schmidt JJ, Rowley J, Kong HJ. Hydrogels used for cell-based drug delivery. J Biomed Mater Res A 2009; 87:1113-22. [PMID: 18837425 DOI: 10.1002/jbm.a.32287] [Citation(s) in RCA: 144] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Stem cells, progenitor cells, and lineage-committed cells are being considered as a new generation of drug depots for the sustained release of therapeutic biomolecules. Hydrogels are often used in conjunction with the therapeutic secreting cells to provide a physical barrier to protect the cells from hostile extrinsic factors. Although the hydrogels significantly improve the therapeutic efficacy of transplanted cells, there have been no successful products commercialized based on these technologies. Recently, biomaterials are increasingly designed to provide cells with both a physical barrier and an extracellular matrix to further improve the secretion of therapeutic proteins from cells. This review will discuss (1) the cell encapsulation process, (2) the immunogenicity of the encapsulating hydrogel, (3) the transport properties of the hydrogel, (4) the hydrogel mechanical properties, and will propose new strategies to improve the hydrogel and cell interaction for successful cell-based drug delivery strategies.
Collapse
Affiliation(s)
- John J Schmidt
- Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61822, USA
| | | | | |
Collapse
|
25
|
Zhang Y, Wang W, Zhou J, Yu W, Zhang X, Guo X, Ma X. Tumor Anti-angiogenic Gene Therapy with Microencapsulated Recombinant CHO Cells. Ann Biomed Eng 2007; 35:605-14. [PMID: 17277990 DOI: 10.1007/s10439-007-9255-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2006] [Accepted: 01/04/2007] [Indexed: 12/24/2022]
Abstract
Microencapsulation of recombinant cells is a novel promising approach to tumor therapy in which therapeutic protein is sustainable and long-term delivered by microencapsulated cells. The semi-permeable membrane of microcapsule can protect cell from host's immune rejection, increase the chemical stability of therapeutic protein and circumvent the problems of toxicity, limited half-lives and variation in circulating levels. Endostatin, a potent and specific angiogenesis inhibitor, could suppress the growth of primary and metastatic lesions in multiple murine tumor models. In this paper, APA microcapsules with high strength kept intact over 35 days and recombinant CHO cells kept the rapid proliferation viability and the continuous endostatin-expression function. The study of tumor treatment showed that the implantation of microencapsulated recombinant CHO cells decreased the neovascularization of tumor tissue by 59.4% and inhibited the B16 melanoma growth by 77.4%. Twenty days after tumor cell injection, 80% of animals treated with microencapsulated CHO-endo cells were alive compared to only 50% of animals in either control or mock control groups. Therefore, continuous delivery of endostatin from microencapsulated recombinant cells represents a feasible approach to tumor therapy.
Collapse
Affiliation(s)
- Ying Zhang
- Laboratory of Biomedical Material Engineering, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P.R. China
| | | | | | | | | | | | | |
Collapse
|
26
|
Zhang Y, Wang W, Xie Y, Yu W, Lv G, Guo X, Xiong Y, Ma X. Optimization of microencapsulated recombinant CHO cell growth, endostatin production, and stability of microcapsulein vivo. J Biomed Mater Res B Appl Biomater 2007; 84:79-88. [PMID: 17497679 DOI: 10.1002/jbm.b.30847] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Microencapsulation of recombinant cells secreting endostatin offers a promising approach to tumor gene therapy in which therapeutic protein is delivered in a sustainable and long-term fashion by encapsulated recombinant cells. However, the studies of cell growth and protein production in vivo are very limited. In this study, the effects of microencapsulation parameters on in vivo cell growth, endostatin production, and microcapsule stability after implantation in the peritoneal cavity of mice were for the first time investigated. Microcapsules with liquid core reached higher cell density and endostatin production at day 18 than microcapsules with solid core. There was no significant difference in stability whether the core of the microcapsule was solid or liquid. Decrease in microcapsule size increased the stability of microcapsule. The microcapsules kept intact in the peritoneal cavity of mice after 36 days of implantation when the microcapsules size was 240 microm in diameter, which gave rise to high endostatin production as well. The optimized microencapsulation conditions for in vivo implantation are liquid core and 240 microm in diameter. This study provides useful information for antiangiogenic gene therapy to tumors using microencapsulated recombinant cells.
Collapse
Affiliation(s)
- Ying Zhang
- Laboratory of Biomedical Material Engineering, Dalian Institute of Chemical Physics, Chinese, Academy of Sciences, Dalian 116023, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Akamatsu K, Yamaguchi T. Novel Preparation Method for Obtaining pH-Responsive Core−Shell Microcapsule Reactors. Ind Eng Chem Res 2006. [DOI: 10.1021/ie060857q] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Kazuki Akamatsu
- Department of Chemical System Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan
| | - Takeo Yamaguchi
- Department of Chemical System Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan
| |
Collapse
|
28
|
de Vos P, de Haan BJ, Kamps JAAM, Faas MM, Kitano T. Zeta‐potentials of alginate‐PLL capsules: A predictive measure for biocompatibility? J Biomed Mater Res A 2006; 80:813-9. [PMID: 17058213 DOI: 10.1002/jbm.a.30979] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Alginate-poly-L-lysine (PLL) microencapsulation of cells is a promising approach to prevent rejection in the absence of immunosuppression. Clinical application, however, is hampered by insufficient insight in factors influencing biocompatibility of the capsules. By now, it has been accepted that not only the chemical composition of the materials applied but also other factors contribute to bioincompatibility. The zeta-potential serves as a measure for the electrical charge of the surface and has been shown to be a predictive value for the interfacial reactions between the biomaterial and the surrounding tissue in other applications. In the present study, we have assessed the streaming potential of alginate-PLL capsules composed of either low-, intermediate-, or high-guluronic (G) alginate to calculate the zeta-potential. The zeta-potentials of the capsules were compared to the biological response against the capsules at 4 weeks after implantation in the rat. We show that high-G and low-G alginates provoke a more severe response in the rat than capsules prepared of intermediate-G alginate. This correlates with a higher zeta-potential of the high-G and low-G alginates and by a change in zeta-potential at lower pH. These lower pH-levels are common directly after implantation as the consequence of a host-response associated with mandatory surgery. Our results suggest that we should not only consider the capsule properties under physiological circumstances to explain bioincompatibility but also the capsule features during common pathophysiological situations.
Collapse
Affiliation(s)
- Paul de Vos
- Department of Pathology and Laboratory Medicine, Section of Medical Biology, Division of Immunoendocrinology, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
| | | | | | | | | |
Collapse
|
29
|
Ma J, Qi W, Xie Y, Wang W, Yu W, Ma X. K562 cell growth activity and metabolism characteristics in APA microencapsulated culture and modeling study. J Biotechnol 2006; 125:242-51. [PMID: 16621095 DOI: 10.1016/j.jbiotec.2006.02.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2005] [Accepted: 02/20/2006] [Indexed: 10/24/2022]
Abstract
Cell microencapsulation is likely to play a major role in cell and transplantation therapies in the next decade. The microcapsules provide a special microenvironment in which cells always have different behaviors compared with free non-encapsulated culture. In this work, the behaviors of K562 leukemia cells were studied once entrapped in solid and liquefied APA microcapsules as well as in free non-encapsulated culture. Glucose pulse culture was employed to characterize the growth and metabolism of microencapsulated K562 cells. And mathematical modeling was presented to develop a basis for the deeper understanding of cells responses to different culture environments. Based on the results of experiments and modeling, it was found that cells presented a better growing pattern and maintain the activity at a higher level for extending time. The concentration of lactate was higher in solid microcapsules culture than that of liquefied microcapsules culture, but the cell number was lower. And the lactate yield coefficients (lactate/glucose) were 0.8129, 0.6978 and 0.601 for free non-encapsulated, solid microcapsules and liquefied microcapsules culture, respectively. An increase of glucose concentration led a decrease of cell activity, The glucose consumption ratio were 99.9%, 86.8%, 49.4% and 28.6% with the decrease in its concentration from 2 to 4, 6, 10 g/L, however, the lactate yield coefficient were 0.7184, 0.6654, 0.8239 and 0.9693, respectively.
Collapse
Affiliation(s)
- Juan Ma
- Laboratory of Biomedical Material Engineering and Department of Science and Technology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, PR China
| | | | | | | | | | | |
Collapse
|
30
|
de Vos P, Faas MM, Strand B, Calafiore R. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 2006; 27:5603-17. [PMID: 16879864 DOI: 10.1016/j.biomaterials.2006.07.010] [Citation(s) in RCA: 350] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2006] [Accepted: 07/11/2006] [Indexed: 01/12/2023]
Abstract
Transplantation of microencapsulated cells is proposed as a therapy for the treatment of a wide variety of diseases since it allows for transplantation of endocrine cells in the absence of undesired immunosuppression. The technology is based on the principle that foreign cells are protected from the host immune system by an artificial membrane. In spite of the simplicity of the concept, progress in the field of immunoisolation has been hampered for many years due to biocompatibility issues. During the last years important advances have been made in the knowledge of the characteristics and requirements capsules have to meet in order to provide optimal biocompatibility and survival of the enveloped tissue. Novel insight shows that not only the capsules material but also the enveloped cells should be hold responsible for loss of a significant portion of the immunoisolated cells and, thus, failure of the grafts on the long term. Microcapsules without cells can be produced as such that they remain free of any significant foreign body response for prolonged periods of time in both experimental animals and humans. New approaches in which newly discovered inflammatory responses are silenced bring the technology of transplantation of immunoisolated cells close to clinical application.
Collapse
Affiliation(s)
- Paul de Vos
- Department of Pathology and Laboratory Medicine, Division of Medical Biology, University Hospital of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.
| | | | | | | |
Collapse
|
31
|
Orive G, De Castro M, Ponce S, Hernández RM, Gascón AR, Bosch M, Alberch J, Pedraz JL. Long-Term Expression of Erythropoietin from Myoblasts Immobilized in Biocompatible and Neovascularized Microcapsules. Mol Ther 2005; 12:283-9. [PMID: 15935736 DOI: 10.1016/j.ymthe.2005.04.002] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2005] [Revised: 04/11/2005] [Accepted: 04/11/2005] [Indexed: 01/03/2023] Open
Abstract
The present paper investigates the long-term functionality of an ex vivo gene therapy approach based on cell microencapsulation for the continuous delivery of erythropoietin (EPO) without implementation of immunosuppressive protocols. Polymer microcapsules (0.5 ml) loaded with EPO-secreting C(2)C(12) myoblasts and releasing 15,490 +/- 600 IU EPO/24 h were implanted in the peritoneum and subcutaneous tissue of syngeneic and allogeneic mice. High and constant hematocrit levels were maintained for more than 100 days in all implanted mice. Capsules retrieved from the peritoneum were free-floating or forming small capsule clusters, and we detected only a weak fibroblast outgrowth in capsules adhered to organs, whereas capsules explanted from the subcutaneous region appeared altogether as a richly vascularized structure with no signs of major host reaction. Interestingly, the functionality of capsules implanted in the allogeneic mice persisted until day 210 after implantation. These results highlight the feasibility of cell encapsulation technology for the long-term delivery of EPO independent of the method of administration and the mouse strain.
Collapse
Affiliation(s)
- G Orive
- Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria-Gasteiz, Spain
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Polymeric artificial cells have the potential to be used for a wide variety of therapeutic applications, such as the encapsulation of transplanted islet cells to treat diabetic patients. Recent advances in biotechnology, molecular biology, nanotechnology and polymer chemistry are now opening up further exciting possibilities in this field. However, it is also recognized that there are several key obstacles to overcome in bringing such approaches into routine clinical use. This review describes the historical development and principles behind polymeric artificial cells, the present state of the art in their therapeutic application, and the promises and challenges for the future.
Collapse
Affiliation(s)
- Thomas Ming Swi Chang
- Artificial Cells and Organs Research Center, Departments of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine, McGill University, 3655, Drummond Street, Montreal, Quebec, Canada H3G 1H6.
| |
Collapse
|
33
|
|
34
|
van Hoogmoed CG, Busscher HJ, de Vos P. Fourier transform infrared spectroscopy studies of alginate-PLL capsules with varying compositions. ACTA ACUST UNITED AC 2003; 67:172-8. [PMID: 14517874 DOI: 10.1002/jbm.a.10086] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Microencapsulation of cells is a promising approach to prevention of rejection in the absence of immunosuppression. Clinical application, however, is hampered by insufficient insight into the factors that influence the biocompatibility of the capsules. Capsules prepared of alginates with a high guluronic (G) acid content proved to be more adequate for clinical application since they are more stable, but, unfortunately, they are less biocompatible than capsules prepared of intermediate-G alginate. In order to get some insight into the physicochemical factors that influence the biocompatibility of capsules for the encapsulation of living cells, the chemical compositions of alginate[bond]Ca beads and alginate[bond]PLL capsules were studied by Fourier transform infrared spectroscopy. We found that during the transition of the alginate[bond]Ca beads to alginate[bond]PLL capsules, Ca connecting the alginate molecules, disappeared at the surface of both high-G and intermediate-G alginate[bond]PLL capsules. At the same time, it turned out that high-G alginate[bond]PLL capsules contained more hydrogen bonding than did intermediate[bond]G alginate capsules. Thus the well-known higher stability of high-G alginate[bond]PLL compared to intermediate-G alginate[bond]PLL capsules is not caused by a higher degree of binding to Ca of the alginate molecules but rather by the presence of more hydrogen bonds. Another observation was that after the transition from bead to capsule, high-G alginate[bond]PLL capsules contained 20% more PLL than the intermediate-G alginate[bond]PLL capsules. Finally, we show that in both high-G and intermediate-G alginate[bond]PLL capsules, the PLL exists in the alpha-helix, in the antiparallel beta-sheet, and in the random coil conformation. This study shows that FT-IR allows for successful analyses of the chemical factors essential for understanding differences in the biocompatibility of alginate[bond]PLL capsules.
Collapse
Affiliation(s)
- Chris G van Hoogmoed
- Department of Biomedical Engineering, Section of Bioadhesion, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
| | | | | |
Collapse
|
35
|
de Vos P, van Hoogmoed CG, de Haan BJ, Busscher HJ. Tissue responses against immunoisolating alginate-PLL capsules in the immediate posttransplant period. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH 2002; 62:430-7. [PMID: 12209929 DOI: 10.1002/jbm.10345] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Alginate-polylysine (PLL) capsules are commonly applied for immunoisolation of living cells for the treatment of a wide variety of diseases. Large-scale application of the technique, however, is hampered by insufficient biocompatibility of the capsules with failure of the grafts as a consequence. Most studies addressing biocompatibility issues of alginate-PLL capsules have focused on the degree of overgrowth on the capsules after graft failure and not on the reaction against the capsules in the immediate posttransplant period. Therefore, capsules were implanted in the peritoneal cavity of rats and retrieved 1, 5, and 7 days later for histological examination and X-ray photoelectron spectroscopy analysis for evaluation of chemical changes at the capsule surface. After implantation, the nitrogen signal increased from 5% on day 0, to 8.6% on day 7, illustrating protein adsorption on the capsule's surface. This increase in protein content of the membrane was accompanied by an increase in the percentage of overgrown capsules from 0.5 +/- 0.3% on day 1 to 3.3 +/- 1.6% on day 7. The cellular overgrowth was composed of monocytes/macrophages, granulocytes, fibroblasts, erythrocytes, multinucleated giant cells, and basophils. This overgrowth was not statical as generally assumed but rather dynamic as illustrated by our observation that at day 1 after implantation we mainly found monocytes/macrophages and granulocytes that on later time points were substituted by fibroblasts. As the inflammatory reaction predictably interfere with survival of encapsulated cells, efforts should be made to suppress activities or recruitment of inflammatory cells. These efforts may be temporary rather than permanent because most inflammatory cells have disappeared after 2 weeks of implantation.
Collapse
Affiliation(s)
- Paul de Vos
- Department of Pathology, Section of Medical Biology, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.
| | | | | | | |
Collapse
|
36
|
de Vos P, Hoogmoed CG, Busscher HJ. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH 2002; 60:252-9. [PMID: 11857431 DOI: 10.1002/jbm.10060] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Transplantation of encapsulated living cells is a promising approach for the treatment of a wide variety of diseases. Large-scale application of the technique, however, is hampered by insufficient biocompatibility of the capsules. In order to get means to study factors influencing the biocompatibility of capsule for encapsulation of living cells, we have correlated the chemical composition of the surface of commonly applied alginate-PLL capsules with the biological response in rats. Capsules prepared of alginates with an intermediate guluronic (G) acid content proved to be biocompatible, whereas capsules prepared of high-G alginates were overgrown by inflammatory cells. We applied X-ray photoelectron spectroscopy to correlate the biological responses with the chemical compositions of the capsule surfaces. High-G alginate capsules proved to have a higher PLL content but less surface binding sites for PLL than low-G alginates. This study, shows for the first time that biological responses against capsules can be successfully correlated to its chemical characteristics.
Collapse
Affiliation(s)
- Paul de Vos
- Department of Pathology and Laboratory Medicine, Section of Medical Biology, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.
| | | | | |
Collapse
|
37
|
Abstract
Entrapment of mammalian cells in physical membranes has been practiced since the early 1950s when it was originally introduced as a basic research tool. The method has since been developed based on the promise of its therapeutic usefulness in tissue transplantation. Encapsulation physically isolates a cell mass from an outside environment and aims to maintain normal cellular physiology within a desired permeability barrier. Numerous encapsulation techniques have been developed over the years. These techniques are generally classified as microencapsulation (involving small spherical vehicles and conformally coated tissues) and macroencapsulation (involving larger flat-sheet and hollow-fiber membranes). This review is intended to summarize techniques of cell encapsulation as well as methods for evaluating the performance of encapsulated cells. The techniques reviewed include microencapsulation with polyelectrolyte complexation emphasizing alginate-polylysine capsules, thermoreversible gelation with agarose as a prototype system, interfacial precipitation and interfacial polymerization, as well as the technology of flat sheet and hollow fiber-based macroencapsulation. Four aspects of encapsulated cells that are critical for the success of the technology, namely the capsule permeability, mechanical properties, immune protection and biocompatibility, have been singled out and methods to evaluate these properties were summarized. Finally, speculations regarding future directions of cell encapsulation research and device development are included from the authors' perspective.
Collapse
Affiliation(s)
- H Uludag
- Department of Biomedical Engineering, 10-102 Clinical Sciences Building, University of Alberta, AB T6G 2G3, Edmonton, Canada.
| | | | | |
Collapse
|
38
|
Rafael E, Gazelius B, Wu GS, Tibell A. Longitudinal studies on the microcirculation around the TheraCyte immunoisolation device, using the laser Doppler technique. Cell Transplant 2000; 9:107-13. [PMID: 10784072 DOI: 10.1177/096368970000900113] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Encapsulation of cellular grafts in an immunoisolation membrane device may make it possible to perform transplantation without having to give immunosuppressive drugs. A common problem is the development of an avascular fibrotic zone around the implants, leading to impaired graft survival. The TheraCyte macroencapsulation device has therefore been designed to facilitate neovascularization of the device's surface. In this study, we evaluated the microcirculation around empty TheraCyte devices implanted SC in rats at various times after implantation, using a laser Doppler probe introduced via the device port. Studies were performed on day 1 or at 1, 2, and 4 weeks or at 2, 3, and 12 months after implantation. The mean flow was 158+/-42, 148+/-50, 133+/-28, 72+/-17, 138+/-41, 165+/-43, and 160+/-29 perfusion units (PU), respectively. Thus, the microcirculation around the device was significantly reduced at 4 weeks after implantation (p < 0.01) while, from 2 months onwards the circulation had improved and did not differ significantly from that on day 1. The present study shows time-related changes in the microcirculatory flow around TheraCyte macroencapsulation devices that agree with our previous microdialysis studies on in vivo exchange of insulin and glucose between the device and the circulation. Laser Doppler flowmetry seems to provide a reliable technique for screening blood perfusion around macroencapsulation devices.
Collapse
Affiliation(s)
- E Rafael
- Department of Transplantation Surgery, Huddinge Hospital, Sweden.
| | | | | | | |
Collapse
|
39
|
Chang TM. Artificial cells with emphasis on bioencapsulation in biotechnology. BIOTECHNOLOGY ANNUAL REVIEW 1998; 1:267-95. [PMID: 9704091 DOI: 10.1016/s1387-2656(08)70054-1] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The most common use of artificial cells is for bioencapsulation of biologically active materials. Each artificial cell can contain combinations of materials. The permeability, composition and shape of an artificial cell membrane can be varied using different types of synthetic or biological materials. These possible variations in contents and membranes allow for large variations in the properties and functions of artificial cells. Artificial cells containing adsorbents have been a routine form of treatment in hemoperfusion for patients. This includes acute poisoning, high blood aluminum and iron, and supplement to dialysis in kidney failure. Artificial red blood cell substitutes based on modified hemoglobin are already in Phase I and Phase II clinical trials in patients. Artificial cell encapsulated cell cultures are being studied for the treatment of diabetes, liver failure, gene therapy and other conditions. Research on artificial cells containing enzymes includes their use for treatment in hereditary enzyme deficiency diseases and other diseases. Recent demonstration of extensive enterorecirculation of amino acids in the intestine has allowed oral administration to deplete specific amino acids. One example is phenylketonuria, an inborn error or metabolism resulting in high systemic phenylalanine levels. Preliminary clinical studies in patients using bioencapsulation of cells or enzymes have started. Artificial cells containing complex enzyme systems convert wastes like urea and ammonia into essential amino acids. Artificial cells are being used for the production of monoclonal antibodies, interferon and other biotechnological products. Other areas of biotechnological uses include drug delivery, and other areas of biotechnology, chemical engineering and medicine.
Collapse
Affiliation(s)
- T M Chang
- Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
40
|
Chang TM. Pharmaceutical and therapeutic applications of artificial cells including microencapsulation. Eur J Pharm Biopharm 1998; 45:3-8. [PMID: 9689530 DOI: 10.1016/s0939-6411(97)00117-3] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Artificial cells for pharmaceutical and therapeutic applications started as microencapsulation on the micron scale. This has now expanded up to the higher range of macrocapsules and down to the nanometer range of nanocapsules and even to the macromolecular range of cross-linked hemoglobin as blood substitutes. This author first reported microencapsulation of biologically active material in 1957 (T.M.S. Chang, Hemoglobin corpuscles. Research Report for Honours Physiology, Medical Library, McGill University, 1957. (Also reprinted as part of 30th anniversary in Artificial Red Blood Cells Research, J. Biomater. Artif. Cells Artif. Organs 16 (1988) 1-9.) and 1964 (T.M.S. Chang, Semipermeable microcapsules, Science 146 (1964) 524-525). While pharmaceutical research has made use of these approaches for drug delivery, this author has been concentrating on the encapsulation of biotechnological products for therapeutic applications. Therefore, there was little interaction between the two approaches. In the last 10 years, pharmaceutical research, as in other areas of research, has become increasingly interested in biotechnology. Because of this interest, this article is a brief overview of developments of artificial cells for biotechnological products with emphasis on hemoglobin, enzymes, cells and genetically engineered microorganisms.
Collapse
Affiliation(s)
- T M Chang
- Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
41
|
Affiliation(s)
- R P Lanza
- BioHybrid Technologies Inc., Shrewsbury, MA 01545, USA
| | | |
Collapse
|
42
|
Abstract
The use of implantable immunoisolation devices, in which the tissue is protected from immune rejection by enclosure within a semipermeable membrane or encapsulant, is one approach in the development of cell therapies. However, further research is required in the areas of: tissue supply from primary or cell-culture sources; maintenance of cell viability and function, its relationship to device design, and the role of, and factors affecting, oxygen-supply limitations; and, protection from immune rejection, especially in view of the mechanisms thought to operate in the presence of a semipermeable membrane, the properties of that membrane, and the implications for biology and device design.
Collapse
Affiliation(s)
- C K Cotton
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge 02139-4307, USA.
| |
Collapse
|
43
|
Hennington MH, D'Armini AM, Lemasters JJ, Egan TM. Cadaver lungs for transplantation. Effect of ventilation with alveolar gas. Transplantation 1996; 61:1009-14. [PMID: 8623177 DOI: 10.1097/00007890-199604150-00004] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
In an effort to increase the donor pool for lung transplantation (LTX), we have demonstrated the feasibility of LTX from circulation-arrested cadavers in a canine LTX model. We hypothesized that ventilation of the cadaver lung with alveolar gas (20% O2, 5% CO2, balance N2) (AG) would be superior to ventilation with 100% oxygen (O2) after circulatory arrest of the donor. Twelve mongrel dogs were intubated, heparinized and euthanized by pentothal injection and ventilated with AG (n=6) or O2 (n=6). Four hours later, donor animals underwent sternotomy, and the lungs were flushed with cold modified Euro-Collins solution, harvested, and stored inflated in ice slush. Left lung allotransplantation was performed, and recipients were made dependent o n the transplanted lung by occlusion of the contralateral bronchus and pulmonary artery. Recipient animals were ventilated with an FiO2 of 0.4 and followed for 8 hr. Total ischemic time was 7.9 hr for both groups. Pulmonary edema developed in all recipients of AG lungs; one recipient survived the 8-hr observation period with poor oxygenation. In contrast, three of six recipients of O2-ventilated lungs survived for 8-hr with excellent gas exchange. Specimens of donor lungs before and after transplant were evaluated histologically utilizing trypan blue exclusion as an indicator of cell viability. At the time of organ retrieval 4 hr after death, 6% of cells were nonviable in the O2-ventilated cadaver lungs. Circulation-arrested cadaver lungs ventilated with 100% O2 prior to organ retrieval have superior pulmonary function after transplant compared with lungs ventilated with AG. Ventilation of cadaver lungs with AG induces pulmonary injury in this model. retrieval of donor lungs from circulation-arrested cadavers has potential for increasing the pulmonary donor pool.
Collapse
Affiliation(s)
- M H Hennington
- Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, 27599, USA
| | | | | | | |
Collapse
|
44
|
Willaert RG, Baron GV. GEL ENTRAPMENT AND MICRO-ENCAPSULATION: METHODS, APPLICATIONS AND ENGINEERING PRINCIPLES. REV CHEM ENG 1996. [DOI: 10.1515/revce.1996.12.1-2.1] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
Lysaght MJ, Frydel B, Gentile F, Emerich D, Winn S. Recent progress in immunoisolated cell therapy. J Cell Biochem 1994; 56:196-203. [PMID: 7829581 DOI: 10.1002/jcb.240560214] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Biohybrid implants represent a new class of medical device in which living cells, supported in a hydrogel matrix, and surrounded by a semipermiable membrane, produce and deliver therapeutic reagents to specific sites within a host. First proposed in the mid-1970s for diabetes, this treatment modality has progressed rapidly in the past four years and is now being investigated not just for endocrine disorders but also for alleviation of chronic pain, treatment of neurodegenerative disorders, and delivery of neurotrophic factors to sites within the blood brain barrier, and as a practical alternative to conventional ex vivo.
Collapse
Affiliation(s)
- M J Lysaght
- CytoTherapeutics, Inc., Providence, Rhode Island 02906
| | | | | | | | | |
Collapse
|
46
|
Literature Alerts. J Microencapsul 1994. [DOI: 10.3109/02652049409040465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|